US Market News
1週前
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetJuly 2, 2026 1:05 PM
ACCESS NewswireThe tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period. NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.Key Highlights from the Flash Report:Shareholder Loyalty Program via Contingent Value Rights:OSRH plans to distribute one non-transferable CVR for every share held as of the expected record date, at no cost to shareholders. As the Company's share price reaches a series of defined milestones over the twelve months following the record date, shareholders who continuously hold their shares automatically receive additional shares of common stock.Tiered, Cumulative Reward Structure:Rewards are delivered in four tiers: at a share price ≥$2.00 at the 3 month observation date, a CVR delivers 0.5 additional shares; ≥$3.00 at the 6 month observation date delivers 1.0 shares; ≥$4.00 at the 9 month observation date delivers 1.5 shares; and ≥$5.00 at the 12 month observation date delivers 2.0 shares. A shareholder who remains invested through all four milestones over 12 months would theoretically receive five additional shares per original share, growing their position to six times its original size.An Alternative to a Reverse Split:Emerging Growth Research believes the CVR structure is likely the first time a company has used this mechanism to provide an asymmetric upside incentive for shareholders, and views it as preferable to a reverse stock split. Rather than reducing share count and liquidity in a manner that could give short sellers another opportunity to press the stock lower, the program is designed to reward loyal holders with additional shares while potentially improving trading liquidity and discouraging short selling.Building on the $815 Million BCM Europe Licensing Deal:The loyalty program builds on the strategic strength of OSRH's $815 million licensing agreement this year with BCM Europe for VXM01. Emerging Growth Research notes that continued execution on the BCM Europe relationship, growth in 4PL, integration of Woori IO's non-invasive glucose monitor into the global wearables market through Big Tech partnerships, and progress in drug candidate development represent substantial sources of potential price upside.Share Price Dynamics and Potential Floor:OSRH shares have experienced volatility over the past year. Emerging Growth Research believes a potential floor may now be forming in the stock if short sellers are brought to heel by the new loyalty program's design.For a copy of the full flash report, please visit:https://emerginggrowth.com/wp-content/uploads/2026/07/OSRH_Flash-Report_7.2.26.pdf
or
https://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Health, Inc.Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Health, Inc. (Nasdaq: OSRH), formerly OSR Holdings, is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).About Emerging Growth ResearchEmerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.Forward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Health, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the proposed Shareholder Loyalty Program and its record date, legal counsel's opinion, licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that the CVR program is not implemented as currently contemplated or at all, that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints. Contact:Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comSOURCE: Emerging Growth ResearchView the original press release on ACCESS NewswireOriginal: CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
US Market News
1週前
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetJuly 2, 2026 9:00 AM
ACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.Key Highlights From the Flash Report:Shareholder Loyalty Program via Contingent Value Rights:OSRH plans to distribute one non-transferable CVR for every share held as of the expected record date, at no cost to shareholders. As the Company's share price reaches a series of defined milestones over the 12 months following the record date, shareholders who continuously hold their shares automatically receive additional shares of common stock.Tiered, Cumulative Reward Structure:Rewards are delivered in four tiers: at a share price ≥$2.00 sustained for 3 months, a CVR delivers 0.5 additional shares; ≥$3.00 for 6 months delivers 1.0 shares; ≥$4.00 for 9 months delivers 1.5 shares; and ≥$5.00 for 12 months delivers 2.0 shares. A shareholder who remains invested through all four milestones over 12 months would theoretically receive five additional shares per original share, growing their position to six times its original size.An Alternative to a Reverse Split:Emerging Growth Research believes the CVR structure is likely the first time a company has used this mechanism to provide an asymmetric upside incentive for shareholders, and views it as preferable to a reverse stock split. Rather than reducing share count and liquidity in a manner that could give short sellers another opportunity to press the stock lower, the program is designed to reward loyal holders with additional shares while potentially improving trading liquidity and discouraging short selling.Building on the $815 Million BCM Europe Licensing Deal:The loyalty program builds on the strategic strength of OSRH's $815 million licensing agreement this year with BCM Europe for VXM01. Emerging Growth Research notes that continued execution on the BCM Europe relationship, growth in 4PL, integration of Woori IO's non-invasive glucose monitor into the global wearables market through Big Tech partnerships, and progress in drug candidate development represent substantial sources of potential price upside.Share Price Dynamics and Potential Floor:OSRH shares have experienced volatility over the past year. Emerging Growth Research believes a potential floor may now be forming in the stock if short sellers are brought to heel by the new loyalty program's design.For a copy of the full flash report, please visit:https://emerginggrowth.com/wp-content/uploads/2026/05/OSRH_Flash-Report_05.05.26.pdforhttps://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Health, Inc.Founded in 2020 and headquartered in Bellevue, Washington, and Gyeonggi-do, South Korea, OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).About Emerging Growth ResearchEmerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.Contact:
Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comForward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Health, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the proposed Shareholder Loyalty Program and its record date, legal counsel's opinion, licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that the CVR program is not implemented as currently contemplated or at all, that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints. SOURCE: OSR Health, Inc.Related Documents:OSRH_Flash Report_7.2.26View the original press release on ACCESS NewswireOriginal: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
US Market News
2週前
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional SharesJune 25, 2026 8:32 AM
ACCESS NewswireContingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestonesBELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026. One CVR for every share owned. The Board of Directors has authorized management to proceed with implementation, subject to receipt of a legal opinion confirming the applicable securities law requirements have been complied with.The concept is simple. As OSRH share price reaches a series of defined milestones over the twelve months following the record date, shareholders who continuously hold their shares would automatically receive additional shares of common stock, at no additional cost - no purchase, no exercise, and no additional investment required.The CVR ProgramFor every share owned on the record date, a shareholder would receive one CVR. Each CVR can deliver additional shares as the stock reaches higher price levels and the holder stays invested:Tier / Holding PeriodPrice TriggerCVR DeliveryCumulative PositionTier 1 - 3 months≥ $2.000.5 new shares per CVR1.5× original positionTier 2 - 6 months≥ $3.001.0 new shares per CVR2.5× original positionTier 3 - 9 months≥ $4.001.5 new shares per CVR4.0× original positionTier 4 - 12 months≥ $5.002.0 new shares per CVR6.0× original positionThe tiers are cumulative. A shareholder who holds throughout the period, if all four milestones are achieved, would receive a total of five additional shares for each share originally held - growing their position to six times its original size.The program reflects management's belief that OSRH is approaching an important inflection point, supported by catalysts including the VXM01 global licensing opportunity and the U.S. and international market potential for Woori IO's non-invasive glucose monitor."We designed this program for the shareholders who believe in the future OSR Health is building," said Peter Hwang, Chief Executive Officer of OSRH. "Too often, the investors who stay the course get no special recognition for their conviction, and we want to change that. It's an ideal corporate action to welcome in our inflection point - not a mechanical reverse split, but a genuine reward for the loyal shareholders who believe in our vision. As we deliver on our potential and our shareholders stay with us, they share directly in our success: additional shares, not fewer. It's a simple idea, and a deeper alignment between the Company and the people who own it."Asymmetric by DesignThe CVRs work in one direction to only ever deliver additional shares, never take them away. And the reward scales with conviction - as OSRH reaches higher milestones each CVR delivers progressively more shares, building from one and a half times at the first tier to a cumulative six times the original position if every milestone is met. It is upside potential layered on top of the shares investors already own, reserved for those who continue to hold.Because the additional shares are delivered through CVR settlements rather than as a stock dividend or stock split, they are not subject to the automatic, exchange-applied price adjustment (i.e., "ex-dividend") that accompanies those corporate actions. Instead, the Company's share price will continue to reflect underlying fundamental value driven by the market."We're working hard to finalize this program, and it reflects our commitment to finding innovative ways to reward shareholders," said Tim Smith, Head of Investor Relations at OSRH. "With our recent name change to OSR Health and important catalysts ahead for VXM01 and Woori IO, our focus is on executing and building out our pipeline while making sure the shareholders who back us benefit from that progress."Eligibility, Timing, and TermsThe record date is expected on or about July 31, 2026, subject to legal review and finalization of the program. Record-date holders would receive CVRs automatically, at no cost. The CVRs would be non-transferable and would have no standalone value, and only shares held as of the record date would carry CVRs. Continued holding would be required through each measurement period, with holders enrolling and periodically confirming their holdings through the program administrator. A holder who sells or transfers the underlying shares would forfeit the related CVRs; the Company is evaluating how to apply that treatment to lent shares.Distribution and any share deliveries would be subject to an effective registration statement or an available exemption, and other customary conditions. The Company is working with counsel on the securities-law treatment; full terms will be set out in its SEC filings.About OSR Health, Inc.OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.Investor ContactOSR Health, Inc.
Investor Relations
ir@osr-health.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed Shareholder Loyalty Program, its structure and timing, the potential delivery of additional shares, and the Company's business prospects. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Delivery of additional shares under the program is contingent on the satisfaction of specified share-price and continuous-holding conditions, which may not occur, and the program remains subject to required corporate approvals, the effectiveness of a registration statement, applicable Nasdaq listing requirements, and other conditions, any of which may not be satisfied. The CVRs may expire without the delivery of any shares. The trigger prices referenced above are conditions to delivery and are not predictions, targets, or guarantees of future share price, and there can be no assurance that OSR Health's share price will reach any of these levels. The future issuance of additional shares under the program could have a dilutive effect on existing holders. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Health, Inc. undertakes no obligation to update these statements except as required by law.SOURCE: OSR Health, Inc.View the original press release on ACCESS NewswireOriginal: OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
US Market News
3週前
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We DoJune 22, 2026 9:06 AM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company's mission. The change became effective on June 11, 2026 upon the filing of a Certificate of Amendment with the Delaware Secretary of State.The rebrand is a clearer articulation of the Company's identity as a global health innovation platform operating across biotechnology, medical technology, life sciences, and wellness markets. While "OSR Holdings" described a corporate structure, OSR Health more directly reflects the Company's mission to improve health outcomes through science and innovation.Sharper Health StoryThe rebrand comes amid continued progress across OSR Health's lead programs. Vaximm AG's recent definitive out-licensing agreement for VXM01, an oral cancer immunotherapy, ranks among the most significant transactions in the Company's history, with up to $815 million in potential milestones. Meanwhile, Woori IO continues advancing its non-invasive glucose monitoring platform alongside strategic engagements with global participants including Samsung."From the very beginning, our work has been clear: to improve health outcomes through science and innovation across borders," said Peter Hwang, Chief Executive Officer of OSR Health, Inc. "Our new name finally says out loud what our team has been building every single day. OSR Health isn't a change in direction; rather, it's a clearer expression of the path we're on. We're proud of it, and we're ready to build on this."The name change affects only its legal and brand identity. It does not alter the rights of stockholders, the par value or number of authorized shares of common stock, or any other provision of its governing documents. Shares will continue trading on the Nasdaq Capital Market under the ticker symbol "OSRH". The Company's operating subsidiaries, including OSR Holdings Co., Ltd. (Korea), are unaffected by the change.Focus on Value CreationOSR Health continues to advance its value creation framework, evaluating strategic options including partnerships, subsidiary monetizations, spin-offs, and other corporate actions aimed at unlocking shareholder value.The Company believes that, following the VXM01 licensing transaction announced in April, Woori IO represents a potential next value inflection point in light of the FDA's "General Wellness" Guidance issued in January this year. Woori IO's non-invasive CGM technology, if developed in accordance with the FDA's non-medical-grade lifestyle management framework, could be well positioned to make inroads into the large US wearable device market, enabling the Company to capture market share and generate revenues much sooner than through a sole focus on the medical-grade glucose monitoring market."Our name is new, our mission remains the same," said Tim Smith, Head of IR at OSR Health. "We are focused on disciplined execution and on the value-creating opportunities taking shape across our portfolio. We believe the period ahead will demonstrate the strength of what we're building, and we look forward to delivering for our shareholders."About OSR Health, Inc.OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.comInvestor ContactOSR Health, Inc.
Investor Relations
ir@osr-health.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Health, Inc. undertakes no obligation to update these statements except as required by law.SOURCE: OSR Health, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
KeepItRealistic
1月前
$OSRH using AI to help read between the lines of last PR
https://finviz.com/news/359385/ceo-statement-to-shareholders
OSR Holdings (NASDAQ: OSRH) is a small-cap hub-and-spoke biotech/ healthcare holding company with a diversified portfolio of subsidiaries focused on immuno-oncology (especially VXM01), regenerative biologics, noninvasive glucose monitoring (Woori IO, with Samsung ties), and medical device distribution.
The “Value Creation Framework” section in the recent CEO shareholder letter (June 3, 2026) is a classic holding-company signaling language. It explicitly highlights tools like thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions common in public hub-and-spoke biotech structures. They are not announcing anything specific yet, but are “evaluating a full range of tools.”
What the company is likely working on:
• Unlocking value from key assets, especially VXM01 — This oral DNA-based immunotherapy (targeting VEGFR-2 for cancers like glioblastoma) is their flagship. They recently centralized full IP ownership at the parent level via a $30M asset purchase, alongside a major licensing deal with BCM Europe AG (up to $815M in milestones + royalties structured to flow to OSRH shareholders). This setup gives them flexibility for further partnering, sublicensing, royalty monetization, or other structures.
• Similar actions across the portfolio — Other assets include design-augmented biologics (e.g., for spinal fusion/osteoarthritis) and the noninvasive glucose monitor.
The letter specifically calls out ongoing progress with Woori IO and Samsung engagements.
• Corporate transactions to address valuation and compliance — As a micro-cap (~$14-15M market cap) trading near its 52-week low and dealing with Nasdaq minimum bid price compliance, spin-offs or monetizations of mature/specific subsidiaries could let the market value assets more directly (a common play in biotech holdings to narrow the “conglomerate discount”). This also supports Nasdaq listing maintenance without a reverse split (which the CEO has previously downplayed).
In short, they are almost certainly preparing or actively shopping one or more subsidiaries/assets for partnerships, licensing expansions, spin-offs, or partial monetizations. The language is preparatory and reassures shareholders that management is focused on value-unlocking moves rather than just operations. This is typical for holding companies with promising but capital-intensive biotech assets in a tough small-cap environment.
It’s bullish signaling if they execute well (e.g., big pharma partnerships for VXM01 or a clean spin).
US Market News
1月前
CEO Statement to ShareholdersJune 3, 2026 12:05 PM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders,As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:Strategic Focus and Business DevelopmentOver the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform.Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value.Value Creation FrameworkAs a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets.While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors.Nasdaq Compliance UpdateWe continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value.Our focus remains on building sustainable businesses, advancing technologies, creating partnerships, and positioning OSRH to unlock value over time.OutlookThe next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value.We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy.Sincerely,Peter Hwang
Chief Executive Officer
OSR Holdings, Inc.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: CEO Statement to Shareholders
US Market News
1月前
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million TransactionMay 27, 2026 9:06 AM
ACCESS NewswireTransaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent LevelBELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million.The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG ("BCME") for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program.Under the APA, OSRH will acquire the complete VXM01 intellectual property portfolio, including:Global issued and pending patents and patent applicationsProprietary manufacturing know-how and related process technologyRegulatory filings and clinical dataBiological materialsAssigned program-related contracts and agreementsThe VXM01 IP portfolio includes issued and pending patent protection across major global jurisdictions including the United States, Canada, Europe, Japan, China, Korea, and additional territories, with protection extending into 2038."This acquisition advances our strategy of centralizing high-value intellectual property assets at the OSRH parent level," said Peter Hwang, CEO of OSRH. "Under our hub-and-spoke operating model, OSRH acts as the central IP owner, while development and commercialization are executed through affiliated entities and partners. This enhances licensing flexibility and long-term royalty economics, with value accruing to OSRH shareholders."As previously disclosed, OSRH entered into a definitive global exclusive license agreement with BCME on April 29, 2026 relating to the development, commercialization and potential sublicensing of VXM01. Under the agreement:OSRH is eligible to receive up to $815 million in development and commercial milestone paymentsBCME pledged its entire unencumbered OSRH equity stake as collateral for milestone obligationsOSRH retains rights to 100% of downstream royalty economics following BCME cost recovery and preferred return thresholdsOSRH holds a $15 million put option exercisable at $10.00 per share beginning six months after the licensing agreement effective date.Under the terms of the APA, the $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, defined as completion of a Phase 2 clinical study (Phase 2b or equivalent trial pending discussions) of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The agreement also permits OSRH to make voluntary partial payments prior to such milestone event.The centralized IP ownership structure may also facilitate future evaluation of innovative financing and royalty participation structures associated with the VXM01 platform, with additional updates provided as appropriate.About VXM01VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most difficult to treat solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.About OSR HoldingsOSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.comInvestor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated benefits of the transaction, milestone payments, royalty economics, intellectual property rights, future development and commercialization activities relating to VXM01, and the anticipated strategic and financial impact of the transaction. Actual results may differ materially due to various risks and uncertainties, including clinical development risks, regulatory risks, financing risks, commercialization risks and other factors described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
US Market News
2月前
CEO Statement to ShareholdersMay 12, 2026 9:16 AM
ACCESS NewswireA Clear Commitment: No Reverse Stock SplitBELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.This was a deliberate decision, and it reflects our firm conviction.We will not pursue a reverse stock split.Management has evaluated this path and rejected it. We believe reverse splits do not create shareholder value. They are structural maneuvers that leave business fundamentals unchanged. We intend to earn our Nasdaq minimum bid compliance back through organic execution, not financial engineering.Committed to Organic Recovery Driven by Subsidiary MilestonesOn April 29, 2026, OSR Holdings executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to $815 million in potential milestone payments and marking a major milestone for our oncology platform.In parallel, Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration with Samsung Electronics, while also progressing discussions under NDA with Sinopharm.These are the kinds of developments that build real, durable shareholder value. We intend to continue delivering on them.Our Position Is ClearManagement is focused entirely on restoring shareholder value through operational execution and strategic milestone delivery. We believe this is the right path forward for our shareholders, for our business, and for the long-term credibility of OSR Holdings as a public company.There will be no reverse split. We believe the market will come to reflect the fundamental value we are building.Commitment to Nasdaq Compliance Through ExecutionManagement remains fully committed to restoring compliance with Nasdaq's minimum bid requirement through the continued delivery of meaningful corporate milestones and disciplined engagement with the investment community - not through structural actions that do not improve our business fundamentals.While there can be no assurance regarding timing or outcomes, we remain fully engaged with our advisors and Nasdaq as we work toward restoring compliance on our own terms.We appreciate the continued support of our shareholders and remain confident in the long-term opportunities ahead for OSR Holdings.Sincerely,Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: CEO Statement to Shareholders
US Market News
2月前
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price TargetMay 5, 2026 1:05 PM
ACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's execution of an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the global development, commercialization, and out-licensing of VXM01 - a Phase-2b/3 ready oral immunotherapy for glioblastoma multiforme (GBM) and pancreatic cancer. The agreement's specialty-financed structure represents a significant de-risking milestone, with OSRH slated to receive at least $15 million in cash within six months even in a worst-case scenario.Key Highlights from the Flash Report:$815 Million Definitive Exclusive License Agreement with BCME:OSRH executed a definitive exclusive license agreement with BCM Europe AG (BCME) for worldwide development, commercialization, and out-licensing of VXM01. The agreement is structured as an exclusive, global, sublicensable license covering all therapeutic indications and is effective immediately. It is accompanied by a separate Asset Purchase Agreement under which ownership of the VXM01 IP portfolio transfers outright from Vaximm AG to OSRH for $30 million, consolidating IP at the OSRH parent level.Specialty-Financed Structure Provides Significant De-Risking:The agreement's non-traditional structure includes: (1) $815 million in milestone payments to OSRH from BCME, which in turn controls approximately 30% of OSRH shares now collateralized versus an expected $20 million 2026 upfront payment; (2) a protective near-term put entitling OSRH to optionally sell up to $15 million of common stock to BCME at $10.00 per share within six months; and (3) virtually all downstream royalties accruing to OSRH net of BCME's invested capital plus a 15% CAGR threshold return. Together, these terms represent a meaningful de-risking event for shareholders.Woori IO - Named Global Corporate Partners and Commercialization Progress:The Company has attracted impressive named global corporate partners through Woori IO, its non-invasive blood glucose monitoring subsidiary. The combination of the VXM01 licensing deal and continued Woori IO momentum bodes well for management's multi-platform strategy.Share Price Dynamics and Potential Floor:Shares experienced volatility following the announcement of the BCME agreement, only to sharply reverse on short covering. Emerging Growth Research believes a share price floor of approximately $0.40-$0.45 may now be in place, providing a risk-asymmetric entry point for investors.Key Risks and Near-Term Milestones:Risks remain, including OSRH's limited operating history, the early-stage nature of its development programs, and the potential that licensing deal milestones may not be fully realized. Near-term milestones include execution of the Asset Purchase Agreement within the 30-day contractual window and BCME's progress toward a licensee agreement with a major pharmaceutical partner. Potential dilution via an equity line of credit and exercise of the protective put option is also noted.For a copy of the full flash report, please visit:[LINK HERE FOR PDF REPORT]orhttps://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Holdings, Inc.Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (Nasdaq:OSRH) is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).About Emerging Growth ResearchEmerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.Contact:Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comForward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints. SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
US Market News
2月前
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026April 30, 2026 9:15 AM
ACCESS NewswireOSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders.Virtual Presentation DetailsDate: May 7, 2026Time: 4:10 p.m. ETFormat: VXM01 Licensing Overview and Q&ARegistration: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=oshrTim Smith, Head of Investor Relations, will give an in-depth view of the recently executed VXM01 global licensing agreement, followed by a Q&A session. Investors are encouraged to submit questions in advance to Questions@EmergingGrowth.com or during the live event and management will address as many questions as possible.Attendees are encouraged to register in advance. For those unable to attend live, an archived webcast will be available at EmergingGrowth.com, the Emerging Growth YouTube Channel, and in the "Events & Presentations" section of the Company's website OSR-Holdings.com.To view the Company's previous presentation, visit:https://www.youtube.com/watch?v=n7CjcvlFVzw&t=377sAbout the Emerging Growth ConferenceThe Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.All sessions will be conducted through video webcasts and will take place in the Eastern time zone.About OSR HoldingsOSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable U.S. securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
US Market News
2月前
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM EuropeApril 29, 2026 9:50 AM
ACCESS NewswireLargest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholdersBELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2.The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders."This agreement establishes a clear, accountable framework for the development of VXM01," said Peter Hwang, CEO of OSRH. "It ensures OSR Holdings shareholders participate directly in value creation, while BCME remains accountable for its financial commitments."Transaction OverviewLicense: BCME receives an exclusive global license to develop, manufacture, commercialize, and sublicense VXM01Milestones: OSRH to receive up to $815 million in milestone payments tied to clinical, regulatory, and commercial achievementsIP Ownership: OSRH to acquire full VXM01 IP from Vaximm AG under a $30 million asset purchase agreementRoyalties: OSRH to receive 100% of downstream royalties after BCME recovers its investment and preferred returnSecurity: BCME and affiliates pledge 100% of their OSRH shares as collateral for milestone obligationsGoverning Law: Switzerland (Canton of Basel)BCME is the Company's largest shareholder. Accordingly, the Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following consideration of an independent fairness opinion provided by Avance Life Sciences.Taken together, these economics position OSRH to capture the long-term value created through VXM01's development and commercialization.Alignment Through Equity PledgeUnder a separate Pledge Agreement, BCME and affiliates have pledged their entire unencumbered shareholding in OSRH, representing approximately 29.7% as of the signing date, as collateral for the performance of milestone payment obligations of up to $815 million. This structure is designed to:Provide assurance of BCME's financial commitments under the AgreementAlign the economic interests of the largest shareholder with those of public shareholdersSupport milestone performance through a collateral-backed mechanism under the Pledge Agreement"The decision by BCME to pledge its entire stake as collateral reflects strong conviction in the clinical and commercial potential of VXM01," said Tim Smith, Head of Investor Relations. "It aligns all shareholders around advancing this program toward commercialization and delivering meaningful new treatment options to patients."BCME will actively support development of VXM01 and at the same time engage leading global pharmaceutical partners to secure a sublicensing transaction. With economic returns dependent on downstream monetization and its entire OSRH stake pledged as collateral, BCME is structurally incentivized to advance VXM01 and execute a competitive partnering process focused on maximizing value for OSRH shareholders.Additional Value Mechanism: Put OptionThe Agreement also includes a put option under which OSRH may require BCME to purchase up to $15 million of OSRH common stock at a price of $10.00 per share, exercisable no earlier than six months following the effective date. This feature provides additional capital flexibility and further underscores BCME's long-term commitment to OSRH.About VXM01VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most aggressive and treatment-resistant solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.About BCM Europe AGBCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings.About OSR HoldingsOSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding expected development, milestone payments, sublicensing activities, and the potential benefits of the Agreement. These statements are subject to risks and uncertainties, including clinical, regulatory, and market risks, and actual results may differ materially. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
US Market News
3月前
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 9, 2026 9:15 AM
ACCESS NewswireBELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang.Elimination of $2.02 Million Warrant OverhangAs part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.The Company issued a $555,555 convertible note to secure near-term liquidity to support general corporate purposes and the continued execution of strategic priorities.In connection with the warrant retirement, the extinguished warrants were effectively incorporated into the note, bringing the total face value of the instrument to $1,055,555.This structure enables OSR Holdings to eliminate a substantial source of potential dilution at a significant discount to the prior overhang value, representing a highly efficient balance sheet optimization.Premium Conversion Price at $1.00 per ShareThe convertible note is structured with a fixed conversion price of $1.00 per share, representing approximately a 100% premium to the Company's most recent closing price of approximately $0.49 on April 8, 2026.The premium conversion price reflects a shared alignment with long-term shareholder value and stands in contrast to conventional discounted convertible structures.The $1.00 level is also strategically aligned with the Company's objective of maintaining compliance with NASDAQ minimum bid requirements.Six-Month Conversion RestrictionThe note was issued as a private placement without a registration statement:Accordingly, the note includes a six-month restriction on conversion, ensuring that no shares may be issued into the public float during this period.This feature further supports near-term trading stability by preventing immediate dilution following the transaction.Management Commentary"This transaction is fundamentally about removing structural overhang and strengthening our equity story," said Peter Hwang, CEO of OSR Holdings. "By retiring over $2 million in warrant overhang into a tightly structured instrument, we are meaningfully cleaning up our cap table. Furthermore, the $1.00 conversion price and six-month restriction demonstrate a shared commitment by our investor to stabilizing our valuation as we focus on regaining NASDAQ minimum bid compliance."The Company believes this transaction represents a meaningful step in optimizing its capital structure, removing technical barriers to equity performance, and securing near-term capital to advance its strategic priorities across its immunotherapy, degenerative disease, and medtech platforms.Further details regarding this transaction will be included in the Company's filings with the U.S. Securities and Exchange Commission.About White Lion GBM Innovation FundThe White Lion GBM Innovation Fund, one of Innovate GBM's core sponsors, focuses on strategic funding opportunities in glioblastoma drug development. The Innovation Fund leverages the ecosystem curated by Innovate GBM to gain insights from the GBM community-including neuro-oncologists, scientists, and patient advocacy groups-to guide capital allocation toward the most impactful opportunities.About OSR Holdings, Inc.OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.Investor ContactOSR Holdings, Inc.
Investor Relations
ir@osr-holdings.comForward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company's capital structure, liquidity, and expected benefits of the financing. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
KeepItRealistic
3月前
$OSRH DD is your friend 👇
what is BCME goals in its funding strategy for Vaximm
BCM Europe AG (BCME) is a Switzerland-based life sciences investment entity that functions primarily as a development-stage biotech financier and licensing intermediary. Core Goals and Business ModelIts main objective in deals like the VXM01 transaction is to act as a bridge between early-stage biotech assets (often from smaller companies or subsidiaries) and larger pharmaceutical partners.
Specifically:• Bridge development and de-risk assets: BCME takes on assets like VXM01, funds or supports further clinical development (via dedicated investment vehicles/funds), and advances them to a point where they can be out-licensed to a major pharma company for global commercialization.
• Generate returns through milestones and royalties: By licensing in assets with high potential (e.g., up to $815M milestones + royalties in the OSRH/Vaximm deal), they aim to capture upside from successful development milestones, regulatory approvals, and commercial sales while passing through economics (with recovery mechanisms) to stakeholders.
• Leverage specialized vehicles: They establish dedicated funds (e.g., the tentatively named BCM Decentralized Science Investors I, LP) anchored by strategic investors. These vehicles handle the licensing, development financing, and eventual partnering.
In short, BCME’s strategy focuses on value creation through active intermediation — providing capital, operational support, and partnering expertise to accelerate programs that might otherwise struggle for funding or visibility, while aligning with its position as OSRH’s largest shareholder. This model reduces risk for the original biotech owners (by offloading late-stage costs) and creates multiple return pathways for BCME’s investors.
Note that public information on BCME is limited mostly to press releases and SEC filings tied to OSRH/Vaximm; it does not appear to have a highly visible independent website or broad portfolio disclosures. This structure is common for niche Swiss life sciences investment groups focused on targeted, high-upside deals rather than broad public marketing.
This fits the ongoing OSRH deal well — BCME is stepping in to fund/advance VXM01 toward a bigger pharma exit.
KeepItRealistic
3月前
$OSRH $815 million binding term sheet details
https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea028505701ex10-1.htm
It’s a binding term sheet, with a final executed license agreement targeted for late April 2026.
BCM Europe is already a major shareholder, suggesting alignment. Milestones (if hit) could be transformative for a company this size. Recent analyst coverage (e.g., Emerging Growth Research) has been bullish with high price targets.
The core economics (milestones and development support) involve no immediate equity issuance or heavy dilution. The $15M equity option is optional for OSR, at a premium price ($10/share vs. current ~$0.55), and would only happen if the company chooses it for funding. This limits involuntary dilution compared to typical PIPEs, convertibles, or ATM offerings at market prices.
If exercised, it would add shares (roughly 1.5M at $10), which is material but at favorable terms.
This looks like a strategic, potentially high-upside licensing move designed to minimize dilution and bring value to the parent level.
US Market News
3月前
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetMarch 27, 2026 9:00 AM
ACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.Key Highlights from the Flash Report:Global Licensing Interest in Woori IO:OSRH recently announced interest from multiple regions, including Japan, Korea, India, Israel, and the United States, for its non-invasive glucose monitoring technology. The Company is exploring potential licensing and distribution pathways as part of its broader commercialization strategy.NDA Signed with Sinopharm:OSRH has entered into a non-disclosure agreement with Sinopharm, a large Chinese state-owned pharmaceutical and distribution company. The agreement facilitates information exchange related to regulatory, clinical, and commercial pathways for Woori IO within the Chinese diabetes care market.Additional Validation of Strategic Direction:The announcement represents a second notable development in recent months, following the previously disclosed licensing term sheet with BCM Europe AG (BCME) for VXM01. Together, these developments support management's ongoing efforts to advance both its therapeutic and medical device platforms.Potential Near-Term Milestones:The Company is expected to work toward a definitive agreement with BCME related to the VXM01 licensing structure, which carries a potential milestone value of up to $815 million. The updated deal structure is intended to position OSRH as the primary counterparty.Positioning for Capital Formation:Management continues to engage with institutional investors, and the evolving licensing framework may support future capital raising efforts.Emerging Growth Research notes that while these developments are constructive, risks remain, including the early-stage nature of certain programs, the non-binding status of some agreements, and potential dilution from future financing activities.For a copy of the full flash report, please visit:https://emerginggrowth.com/wp-content/uploads/2026/03/OSRH_Flash-Report_03.26.26.pdforhttps://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)About OSR Holdings, Inc.Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (Nasdaq:OSRH) is a global healthcare holding company with operations in Korea and Switzerland. The Company has subsidiaries focused on the development of oral immunotherapies for cancer, biologics for degenerative diseases, and non-invasive glucose monitoring technology. OSRH also distributes medical devices and is expanding into 4th party logistics (4PL).Contact:Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.comForward-Looking StatementsThis press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that non-binding agreements do not result in definitive transactions, regulatory challenges, and financing constraints. SOURCE: OSR Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
glenn1919
2月前
Zorro
2月前
hondaboost
2月前
Zardiw
2月前
stressfreeliving
3月前
メールアドレスで登録
